Episode 43: Spoilt for choice - the many treatments now available for AMD and DME
Following the approval of Aflibercept 8mg, clinicians in Europe now have 5 anti-VEGF treatments to choose from, not to mention biosimilars. How should we treat patients with so many options open to us? Sandrine Zweifel (Switzerland) and Stela Vujosevic (Italy) compare notes
Create your
podcast in
minutes
It is Free